Lori Hu

A clinical-stage biopharmaceutical company advancing the development of new biologics for cancer treatment. TORL-Bio was founded in 2018 and is focused on the development of novel antibody-based therapeutics for cancer patients. TORL has currently 3 therapeutics in Ph1 clinical trials in indications such as NSCLC, gastric, pancreatic and ovarian cancers

Implantable Shock Absorbers for Knee OA

lvantis, Inc. is a company committed to expanding patient treatment and improving outcomes through new and innovative minimally invasive glaucoma surgical (MIGS) solutions, the fastest growing segment of the ophthalmology market.

A clinical-stage biopharmaceutical company advancing the development of new biologics for cancer treatment. TORL-Bio was founded in 2018 and is focused on the development of novel antibody-based therapeutics for cancer patients. TORL has currently 3 therapeutics in Ph1 clinical trials in indications such as NSCLC, gastric, pancreatic and ovarian cancers

Vertex Ventures HC is part of a global venture fund network under Vertex Holdings. Vertex Ventures HC invests globally in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health, with ~$400 million of assets under management.

Implantable Shock Absorbers for Knee OA

lvantis, Inc. is a company committed to expanding patient treatment and improving outcomes through new and innovative minimally invasive glaucoma surgical (MIGS) solutions, the fastest growing segment of the ophthalmology market.

SR One Capital Management is a transatlantic biotech venture capital firm that seeks to partner with who we believe to be top entrepreneurs, scientists and investment partners in an effort to build elite biotechnology companies. SR One’s mission is to translate innovative technologies into potential next-generation medicines that benefit patients with significant unmet medical needs. SR One has offices in San Francisco, CA and London, UK. For more information, please visit www.srone.com.